Epigenetic Regulation of Longevity-Associated Genes and Clinical Correlates in Aging: Insights from Cancer History and Hematologic Parameters
Abstract
DNA methylation of key tumor suppressor and longevity genes, including TP53, SIRT1, and FOXO3A, changes with age and may reflect cancer history and hematologic status. Using publicly available methylation datasets from whole blood, we analyzed promoter methylation patterns in individuals aged 65–74, 75–84, and 85+, stratified by cancer history, complete blood count (CBC) profile, and red cell distribution width (RDW). Distinct, age-specific trends emerged: in younger elderly groups, TP53 and SIRT1 methylation differed significantly between cancer and non-cancer cases, while FOXO3A methylation correlated with elevated RDW. In the oldest group, higher SIRT1 methylation was seen in cancer-free individuals with normal CBC results, with TP53 and FOXO3A showing smaller variations. These findings highlight the potential of targeted methylation profiling as a minimally invasive biomarker approach for assessing biological aging and disease vulnerability in older populations
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.